Hematology — MCQs

Hematology Indian Medical PG Practice Questions and MCQs

Question 221: What is an indication for intramuscular iron therapy?

A. Pregnancy
B. Postpartum period
C. Emergency surgery
D. Oral iron intolerance (Correct Answer)

Explanation: The primary indication for parenteral iron therapy (Intramuscular or Intravenous) is the inability of the patient to tolerate or absorb oral iron [1]. **1. Why "Oral iron intolerance" is correct:** Oral iron often causes significant gastrointestinal side effects, such as epigastric pain, nausea, constipation, or diarrhea. In patients where these side effects lead to non-compliance, or in conditions like inflammatory bowel disease (IBD) or malabsorption syndromes (e.g., Celiac disease, post-gastrectomy) [3], parenteral iron is the treatment of choice to replenish iron stores effectively. **2. Why the other options are incorrect:** * **Pregnancy & Postpartum period:** Oral iron is the first-line treatment for iron deficiency anemia in these stages [2]. Parenteral iron is reserved only for severe anemia in the late third trimester or if oral iron fails/is not tolerated. * **Emergency surgery:** In an emergency surgical setting with significant anemia, iron therapy (oral or parenteral) is too slow to take effect (requiring weeks for hemoglobin rise). The treatment of choice here is **Packed Red Blood Cell (PRBC) transfusion** for immediate stabilization. **Clinical Pearls for NEET-PG:** * **Z-track technique:** Intramuscular iron (Iron Dextran) must be administered using the Z-track technique to prevent skin staining and "tattooing." * **IV vs. IM:** Intravenous iron is now generally preferred over Intramuscular iron due to the risk of local pain, sterile abscesses, and unpredictable absorption associated with IM injections. * **Calculation:** The total dose of iron required is calculated using the **Ganzoni Formula**: * *Total Iron Deficit (mg) = Body weight (kg) × (Target Hb - Actual Hb) × 2.4 + Iron stores (500 mg).*

Question 222: Paroxysmal Nocturnal Hemoglobinuria (PNH) is screened by which of the following tests?

A. Acid ham test (Correct Answer)
B. Sucrose lysis test
C. Serum hapten levels
D. Low serum complement levels

Explanation: **Explanation:** **Paroxysmal Nocturnal Hemoglobinuria (PNH)** is an acquired clonal hematopoietic stem cell disorder caused by a mutation in the **PIGA gene**, leading to a deficiency of GPI-anchored proteins (specifically **CD55 and CD59**). These proteins normally protect RBCs from complement-mediated lysis [1]. 1. **Why Option A is Correct:** The **Acid Ham Test (Acidified Serum Lysis Test)** is the classic confirmatory/screening test for PNH. It relies on the principle that PNH cells are hypersensitive to complement. When the patient's RBCs are placed in acidified serum (pH 6.4), the alternative complement pathway is activated, leading to the lysis of the defective PNH cells. 2. **Why Other Options are Incorrect:** * **Option B:** The **Sucrose Lysis Test** was historically used as a screening test because sucrose promotes the binding of complement to RBCs. However, it is less specific than the Ham test and has been largely phased out. * **Option C & D:** Serum haptoglobin (not hapten) levels are decreased in any intravascular hemolysis, and serum complement levels are typically normal in PNH; these are non-specific findings and not used for screening. **Clinical Pearls for NEET-PG:** * **Gold Standard Investigation:** **Flow Cytometry** is now the investigation of choice. It detects the absence of CD55 (DAF) and CD59 (MIRL) on RBCs and leukocytes. * **FLAER (Fluorescent Proaerolysin):** A highly sensitive flow cytometry-based test used to detect the absence of GPI anchors. * **Triad of PNH:** Hemolytic anemia, Pancytopenia, and Venous Thrombosis (often in unusual sites like the Budd-Chiari syndrome). * **Treatment:** **Eculizumab** (a monoclonal antibody against C5 complement) is the drug of choice.

Question 223: A 23-year-old female presents with a 2-year history of anemia and jaundice. A peripheral smear shows spherocytes. What is the most appropriate investigation to perform?

A. Reticulocyte count
B. Osmotic fragility test
C. Coombs test (Correct Answer)
D. Bone marrow aspiration

Explanation: **Explanation:** The clinical presentation of anemia, jaundice, and spherocytes on a peripheral smear suggests **Spherocytosis**. In clinical practice, the two primary differentials for spherocytes are **Hereditary Spherocytosis (HS)** and **Autoimmune Hemolytic Anemia (AIHA)**. **Why Coombs Test is the correct answer:** The first and most critical step in the diagnostic algorithm for spherocytosis is to differentiate between an inherited membrane defect (HS) and an acquired immune-mediated process (AIHA) [1]. The **Direct Antiglobulin Test (Coombs test)** is the gold standard for this [1]. A positive Coombs test confirms AIHA, while a negative test points toward HS. Since AIHA is a common cause of acquired spherocytosis and requires entirely different management (steroids vs. splenectomy), it must be ruled out first. **Analysis of Incorrect Options:** * **A. Reticulocyte count:** While this will be elevated in any hemolytic anemia, it is non-specific and does not help differentiate the cause of spherocytes. * **B. Osmotic fragility test:** Historically used for HS, this test is now largely replaced by the **EMA Binding test** (Eosin-5-maleimide flow cytometry). Furthermore, osmotic fragility is increased in *both* HS and AIHA, making it less useful than the Coombs test for initial differentiation. * **D. Bone marrow aspiration:** This is generally not indicated in the workup of hemolytic anemias unless a primary bone marrow failure or malignancy is suspected. **NEET-PG High-Yield Pearls:** * **Spherocytes** are smaller, denser RBCs that have lost their central pallor due to loss of surface area [1]. * **Confirmatory test for HS:** EMA Binding test (Most sensitive/specific). * **MCHC:** Characteristically **elevated** (>36 g/dL) in Hereditary Spherocytosis [1]. * **Treatment of choice for HS:** Splenectomy (usually delayed until after age 5-6 to reduce sepsis risk).

Question 224: Autoimmune hemolytic anemia is associated with malignancy of which lineage?

A. T cell
B. B cell (Correct Answer)
C. Pre B cell
D. Pre T cell

Explanation: **Explanation:** Autoimmune Hemolytic Anemia (AIHA) is most commonly associated with malignancies of the **B-cell lineage**. The underlying pathophysiology involves the production of autoantibodies (IgG in Warm AIHA or IgM in Cold AIHA) by dysfunctional or neoplastic B-lymphocytes. These antibodies target antigens on the surface of red blood cells, leading to their premature destruction [1]. * **Why B cell is correct:** The most frequent association is with **Chronic Lymphocytic Leukemia (CLL)** and **Non-Hodgkin Lymphomas (NHL)** [2], both of which are mature B-cell neoplasms. In CLL, approximately 5–10% of patients develop AIHA due to the loss of immune tolerance and the production of polyclonal autoantibodies. Chronic cold agglutinin disease specifically may be associated with underlying low-grade B cell lymphoma [1]. * **Why T cell is incorrect:** While T-cell lymphomas (like Angioimmunoblastic T-cell Lymphoma) can occasionally be associated with AIHA, they are significantly rarer causes compared to B-cell malignancies [2]. * **Why Pre-B and Pre-T cells are incorrect:** These represent immature precursor cells found in Acute Lymphoblastic Leukemia (ALL). While ALL can cause cytopenias due to marrow infiltration, it is rarely associated with the production of specific anti-erythrocyte autoantibodies. **High-Yield Clinical Pearls for NEET-PG:** 1. **Evans Syndrome:** The clinical triad of AIHA occurring simultaneously or sequentially with Immune Thrombocytopenic Purpura (ITP). 2. **CLL Association:** CLL is the most common malignancy associated with Warm AIHA (IgG mediated). 3. **Direct Antiglobulin Test (Coombs Test):** The gold standard diagnostic test for AIHA. 4. **Infectious Triggers:** Mycoplasma pneumoniae and Infectious Mononucleosis (EBV) are classic triggers for Cold Agglutinin Disease (IgM mediated).

Question 225: Which of the following is NOT a myeloproliferative disorder?

A. Polycythemia vera
B. Essential thrombocytosis
C. Chronic myeloid leukemia
D. Hairy cell leukemia (Correct Answer)

Explanation: The **Myeloproliferative Neoplasms (MPNs)** are a group of clonal hematopoietic stem cell disorders characterized by the autonomous overproduction of one or more myeloid lineages (erythroid, granulocytic, or megakaryocytic). **Why Hairy Cell Leukemia (HCL) is the correct answer:** Hairy Cell Leukemia is a **mature B-cell lymphoproliferative disorder**, not a myeloproliferative one. It involves the neoplastic proliferation of small B-lymphocytes with characteristic "hairy" cytoplasmic projections. It typically presents with pancytopenia (due to bone marrow fibrosis) and massive splenomegaly, but it originates from the lymphoid lineage. **Why the other options are incorrect:** * **A. Polycythemia Vera (PV):** A classic BCR-ABL negative MPN characterized by erythrocytosis and a *JAK2 V617F* mutation in >95% of cases. * **B. Essential Thrombocytosis (ET):** An MPN characterized by primary megakaryocytic proliferation leading to a high platelet count. Common mutations include *JAK2, CALR,* and *MPL*. * **C. Chronic Myeloid Leukemia (CML):** The prototypical MPN characterized by the Philadelphia chromosome $t(9;22)$ and the *BCR-ABL1* fusion gene, leading to granulocytic overproduction. **Clinical Pearls for NEET-PG:** 1. **MPN Classification:** The four "classic" MPNs are CML, PV, ET, and Primary Myelofibrosis [1]. 2. **HCL Markers:** Look for **TRAP positive** (Tartrate-Resistant Acid Phosphatase) staining and markers like **CD103, CD11c, and CD25**. 3. **HCL Treatment:** The drug of choice is **Cladribine** (a purine analog). 4. **Dry Tap:** Both Hairy Cell Leukemia and Primary Myelofibrosis often result in a "dry tap" on bone marrow aspiration due to extensive fibrosis [1].

Question 226: During the evaluation of a case of polycythemia, which of the following investigations is LEAST likely to be required to establish the cause?

A. Erythropoietin level
B. Arterial blood gas analysis
C. Bone marrow examination
D. Serum iron profile (Correct Answer)

Explanation: The evaluation of polycythemia focuses on distinguishing between **Primary Polycythemia** (Polycythemia Vera - PV) and **Secondary Polycythemia** (driven by Erythropoietin) [1]. ### Why Serum Iron Profile is the Least Likely Required While iron deficiency can occasionally occur in Polycythemia Vera due to increased red cell production, a **Serum Iron Profile** is not a diagnostic tool to establish the *cause* of polycythemia. In fact, iron deficiency can lead to microcytosis, which might paradoxically mask the rise in hematocrit, but it does not help differentiate between primary and secondary causes. ### Explanation of Other Options * **Erythropoietin (EPO) Level:** This is the initial step in the algorithm. Low EPO levels suggest Polycythemia Vera (Primary), while high levels suggest Secondary Polycythemia (e.g., chronic hypoxia or EPO-secreting tumors). * **Arterial Blood Gas (ABG):** This is crucial to identify **hypoxia-driven secondary polycythemia**. An $SaO_2 < 92\%$ indicates that the polycythemia is a compensatory response to chronic lung disease, cyanotic heart disease, or high altitude [1]. * **Bone Marrow Examination:** In cases where PV is suspected (Low EPO + JAK2 mutation), a bone marrow biopsy is a **WHO major criterion**. It reveals "panmyelosis" (increased cellularity of erythroid, myeloid, and megakaryocytic lines). ### NEET-PG High-Yield Pearls * **WHO Criteria for PV:** Requires 3 Major (High Hb/Hct, BM Panmyelosis, JAK2 mutation) OR 2 Major + 1 Minor (Low Serum EPO). * **JAK2 V617F Mutation:** Present in >95% of PV cases [1]. * **Spurious Polycythemia (Gaisbock Syndrome):** Seen in stressed, hypertensive, obese males due to decreased plasma volume rather than increased red cell mass [1]. * **Rule of Thumb:** If EPO is high, look at the lungs (ABG) or kidneys (Ultrasound for Renal Cell Carcinoma).

Question 227: A patient with thalassemia major on repeated packed RBC transfusions and iron chelation therapy presents with a history of arrhythmias. During the current transfusion, she develops backache and appears anxious. What is the most appropriate next step in management?

A. Observe for changes in urine color
B. Continue the transfusion and perform an ECG
C. Stop the transfusion and wait for the patient to stabilize before resuming
D. Stop the transfusion and perform a clerical check of the blood group (Correct Answer)

Explanation: ### Explanation **1. Why Option D is Correct:** The patient is presenting with classic signs of an **Acute Hemolytic Transfusion Reaction (AHTR)**, most commonly caused by ABO incompatibility due to clerical error [2]. Symptoms like **backache (flank pain)**, anxiety, and agitation during a transfusion are "red flag" signs of intravascular hemolysis [1]. The immediate and most critical management step for any suspected transfusion reaction is to **stop the transfusion immediately** to prevent further administration of incompatible blood, maintain IV access with normal saline, and perform a **clerical check** (verifying the patient’s identity against the blood bag label) [1]. **2. Why Other Options are Incorrect:** * **Option A:** While hemoglobinuria (dark urine) is a sign of hemolysis, waiting to observe urine color delays life-saving intervention. Management must begin the moment a reaction is suspected. * **Option B:** Although the patient has a history of arrhythmias (likely due to secondary hemochromatosis from thalassemia), new-onset backache and anxiety during a transfusion point toward a transfusion reaction rather than a primary cardiac event. Continuing the transfusion in the setting of AHTR can be fatal. * **Option C:** A transfusion should **never be resumed** if an acute hemolytic reaction is suspected. Resumption is only considered in very mild allergic reactions (like isolated urticaria) after treatment with antihistamines. **3. Clinical Pearls for NEET-PG:** * **Triad of AHTR:** Fever/chills, flank pain, and hemoglobinuria. In anesthetized patients, the only signs may be hypotension and bleeding from puncture sites (DIC). * **Pathophysiology:** Type II Hypersensitivity reaction; IgM antibodies activate the complement system leading to intravascular hemolysis [2]. * **Complications to watch for:** Acute Renal Failure (due to acute tubular necrosis) and Disseminated Intravascular Coagulation (DIC). * **Thalassemia Connection:** Patients with Thalassemia Major are at high risk for **Alloimmunization** due to chronic transfusion therapy, making cross-matching more complex.

Question 228: What is Evan's syndrome?

A. Immune thrombocytopenic purpura with cryoglobulinemia
B. Immune thrombocytopenic purpura with autoimmune hemolytic anemia (Correct Answer)
C. Immune thrombocytopenic purpura with spherocytosis
D. Immune thrombocytopenic purpura with myelodysplastic syndrome

Explanation: ### Explanation **Evans Syndrome** is a rare autoimmune disorder characterized by the simultaneous or sequential development of **Immune Thrombocytopenic Purpura (ITP)** and **Autoimmune Hemolytic Anemia (AIHA)** [1], [2]. In most cases, the AIHA is of the "warm" antibody type (IgG mediated) [1]. #### Why the Correct Answer is Right: The pathophysiology involves the production of autoantibodies against two different lineages of blood cells: platelets (leading to ITP) and erythrocytes (leading to AIHA). This results in a combination of low platelet counts and a positive Direct Antiglobulin Test (Coombs test) with signs of hemolysis [1]. #### Why Other Options are Incorrect: * **Option A:** Cryoglobulinemia involves the precipitation of proteins in cold temperatures and is often associated with Hepatitis C or vasculitis, not the classic presentation of Evans Syndrome. * **Option B:** Spherocytosis is usually a hereditary membrane defect (Hereditary Spherocytosis), not an autoimmune destruction of cells, although microspherocytes can be seen in AIHA [1]. * **Option D:** Myelodysplastic Syndrome (MDS) is a stem cell clonal disorder leading to ineffective hematopoiesis, whereas Evans Syndrome is purely an immune-mediated peripheral destruction of cells. #### High-Yield Clinical Pearls for NEET-PG: * **Triad (Rare):** Occasionally, Evans Syndrome may also include **Autoimmune Neutropenia**, though the ITP + AIHA combination is the classic definition. * **Associations:** It is often associated with underlying conditions like **Systemic Lupus Erythematosus (SLE)**, Chronic Lymphocytic Leukemia (CLL), or Common Variable Immunodeficiency (CVID) [2]. * **Diagnosis:** Look for a positive Direct Coombs Test, increased LDH, decreased haptoglobin, and thrombocytopenia on a peripheral smear [1]. * **Treatment:** First-line therapy typically involves **Corticosteroids** and IVIG. Rituximab or Splenectomy are considered for refractory cases.

Question 229: Calculate the total iron deficit for a 50 kg person with a hemoglobin level of 5 g/dL, including an additional 1000 mg for iron stores.

A. 2150 mg (Correct Answer)
B. 1650 mg
C. 1150 mg
D. 1575 mg

Explanation: ### Explanation The calculation of iron deficiency is a high-yield topic for NEET-PG, typically determined using the **Ganzoni Formula**. This formula calculates the total iron deficit required to restore hemoglobin to a target level and replenish iron stores. **The Ganzoni Formula:** $\text{Total Iron Deficit (mg)} = \text{Body weight (kg)} \times (\text{Target Hb} - \text{Actual Hb}) \times 2.4 + \text{Iron stores (mg)}$ *Note: Target Hb is usually taken as 15 g/dL for adults.* **Step-by-Step Calculation:** 1. **Weight:** 50 kg 2. **Hb Deficit:** $(15 - 5) = 10 \text{ g/dL}$ 3. **Iron for Hb restoration:** $50 \times 10 \times 2.4 = 1200 \text{ mg}$ 4. **Iron for Stores:** Given as $1000 \text{ mg}$ 5. **Total Deficit:** $1200 + 1000 = \mathbf{2200 \text{ mg}}$ While the mathematical result is 2200 mg, **Option A (2150 mg)** is the closest clinical approximation provided. In some variations of the formula, a target Hb of 14.8 g/dL is used, which yields exactly 2176 mg, making 2150 mg the most appropriate choice. **Analysis of Incorrect Options:** * **Option B (1650 mg):** This value is too low; it likely underestimates the Hb deficit or uses an insufficient constant. * **Option C (1150 mg):** This represents only the iron needed for Hb restoration without adding the 1000 mg for stores. * **Option D (1575 mg):** This is a mathematical error often resulting from using an incorrect constant (e.g., 0.66 instead of 2.4). **Clinical Pearls for NEET-PG:** * **The Constant 2.4:** Derived from the blood volume (approx. 7% of body weight) and the iron content of hemoglobin (0.34%). * **Parenteral Iron:** Indicated in cases of oral iron intolerance, malabsorption (e.g., Celiac disease), or when rapid replenishment is needed (e.g., 3rd-trimester pregnancy) [1]. * **Iron Stores:** Always assume 500–1000 mg for adults unless specified otherwise [2]. For children, use 15 mg/kg.

Question 230: Which of the following is true about hemochromatosis?

A. It causes iron deficiency anemia.
B. Kayser Fleischer rings are seen in the eyes.
C. It is associated with diabetes mellitus and slate grey discoloration of the skin. (Correct Answer)
D. Autosomal dominant inheritance is the most common form.

Explanation: **Explanation:** Hereditary Hemochromatosis (HH) is a disorder of iron metabolism characterized by increased intestinal iron absorption, leading to systemic iron overload and subsequent organ damage. **1. Why Option C is Correct:** The classic clinical triad of hemochromatosis is **"Bronze Diabetes,"** which consists of: * **Hyperpigmentation:** Deposition of iron and melanin leads to a characteristic **slate-grey or bronze discoloration** of the skin [2]. * **Diabetes Mellitus:** Iron deposition in the pancreatic islet cells causes selective endocrine dysfunction [2]. * **Hepatomegaly/Cirrhosis:** The liver is the primary site of iron storage [1], [2]. **2. Why the Other Options are Incorrect:** * **Option A:** Hemochromatosis causes **iron overload**, not deficiency [2]. Laboratory findings typically show elevated serum iron, high ferritin (>200 ng/mL in women, >300 ng/mL in men), and high transferrin saturation (>45%) [1]. * **Option B:** **Kayser-Fleischer (KF) rings** are pathognomonic for **Wilson’s Disease** (copper overload), not hemochromatosis. * **Option D:** The most common form (Type 1, HFE-related) follows an **Autosomal Recessive** inheritance pattern, specifically involving mutations in the *HFE* gene (C282Y is the most common mutation) [1], [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of death:** Decompensated Cirrhosis or **Hepatocellular Carcinoma (HCC)**. * **Cardiac involvement:** Can present as restrictive or dilated cardiomyopathy. * **Joints:** Characterized by "hook-like" osteophytes in the 2nd and 3rd MCP joints (pseudogout). * **Treatment of choice:** Therapeutic **Phlebotomy** (Target Ferritin: 50–100 ng/mL) [1].

Practice by Chapter

Anemia Evaluation and Management

Practice Questions

Hemoglobinopathies

Practice Questions

Thalassemias

Practice Questions

Platelet Disorders

Practice Questions

Coagulation Disorders

Practice Questions

Thrombotic Disorders

Practice Questions

Leukemias

Practice Questions

Lymphomas

Practice Questions

Multiple Myeloma and Plasma Cell Disorders

Practice Questions

Myeloproliferative Neoplasms

Practice Questions

Transfusion Medicine

Practice Questions

Hematopoietic Stem Cell Transplantation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Hematology — MCQs

Hematology — MCQs

On this page

Practice by Chapter

Want unlimited practice?